JP2012509071A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509071A5
JP2012509071A5 JP2011536741A JP2011536741A JP2012509071A5 JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5 JP 2011536741 A JP2011536741 A JP 2011536741A JP 2011536741 A JP2011536741 A JP 2011536741A JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid construct
invariant chain
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2009/050310 external-priority patent/WO2010057501A1/en
Publication of JP2012509071A publication Critical patent/JP2012509071A/ja
Publication of JP2012509071A5 publication Critical patent/JP2012509071A5/ja
Pending legal-status Critical Current

Links

JP2011536741A 2008-11-21 2009-11-20 免疫応答のプライミング Pending JP2012509071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200801638 2008-11-21
DKPA200801638 2008-11-21
PCT/DK2009/050310 WO2010057501A1 (en) 2008-11-21 2009-11-20 Priming of an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014226711A Division JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング

Publications (2)

Publication Number Publication Date
JP2012509071A JP2012509071A (ja) 2012-04-19
JP2012509071A5 true JP2012509071A5 (cg-RX-API-DMAC7.html) 2013-01-24

Family

ID=40823418

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011536741A Pending JP2012509071A (ja) 2008-11-21 2009-11-20 免疫応答のプライミング
JP2014226711A Pending JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング
JP2017011749A Pending JP2017131220A (ja) 2008-11-21 2017-01-26 免疫応答のプライミング
JP2019091809A Active JP6825036B2 (ja) 2008-11-21 2019-05-15 免疫応答のプライミング

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014226711A Pending JP2015061530A (ja) 2008-11-21 2014-11-07 免疫応答のプライミング
JP2017011749A Pending JP2017131220A (ja) 2008-11-21 2017-01-26 免疫応答のプライミング
JP2019091809A Active JP6825036B2 (ja) 2008-11-21 2019-05-15 免疫応答のプライミング

Country Status (20)

Country Link
US (4) US20110293704A1 (cg-RX-API-DMAC7.html)
EP (3) EP3552622A3 (cg-RX-API-DMAC7.html)
JP (4) JP2012509071A (cg-RX-API-DMAC7.html)
CN (3) CN102292102A (cg-RX-API-DMAC7.html)
AU (1) AU2009317691A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921927B8 (cg-RX-API-DMAC7.html)
CA (1) CA2743229A1 (cg-RX-API-DMAC7.html)
CY (1) CY1122117T1 (cg-RX-API-DMAC7.html)
DK (1) DK2865387T3 (cg-RX-API-DMAC7.html)
ES (1) ES2743677T3 (cg-RX-API-DMAC7.html)
HK (1) HK1209645A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20191594T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045093T2 (cg-RX-API-DMAC7.html)
IL (4) IL212914A0 (cg-RX-API-DMAC7.html)
LT (1) LT2865387T (cg-RX-API-DMAC7.html)
PL (1) PL2865387T3 (cg-RX-API-DMAC7.html)
PT (1) PT2865387T (cg-RX-API-DMAC7.html)
RU (2) RU2017138373A (cg-RX-API-DMAC7.html)
SI (1) SI2865387T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010057501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2121048T3 (en) 2007-02-19 2015-11-23 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
CA2800424C (en) * 2010-06-04 2018-10-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
EP3264090B1 (en) 2011-12-07 2022-05-18 Belgian Volition Srl Method for detecting nucleosome adducts
JP6373836B2 (ja) * 2012-07-26 2018-08-15 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
US10576143B2 (en) 2013-03-15 2020-03-03 Glaxosmithkline Biologicals Sa Poxviral vaccines
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
WO2015024667A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Method for increasing expression of rna-encoded proteins
GB201321384D0 (en) * 2013-12-04 2014-01-15 Isis Innovation Molecular adjuvant
WO2015095952A1 (en) * 2013-12-27 2015-07-02 The Centre For Drug Research And Development Var2csa-drug conjugates
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
KR20250161050A (ko) * 2015-10-12 2025-11-14 난토믹스, 엘엘씨 바이러스성 암 네오에피토프를 위한 조성물 및 방법
EP3389630B1 (en) 2015-12-16 2023-11-08 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
CN109863169A (zh) * 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
IL271965B2 (en) * 2017-07-12 2023-03-01 Nouscom Ag Preparations containing a neoantigenic vaccine for the treatment of cancer
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
EP3703744A1 (en) * 2017-11-03 2020-09-09 Nouscom AG Vaccine t cell enhancer
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
CN108285885A (zh) * 2017-12-28 2018-07-17 中国农业大学 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用
EP3807298A1 (en) 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
SG11202101735PA (en) * 2018-10-19 2021-03-30 Nouscom Ag Teleost invariant chain cancer vaccine
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
RU2725493C2 (ru) * 2018-12-28 2020-07-02 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
EP4137153A1 (en) 2021-08-18 2023-02-22 Sirion Biotech GmbH Therapeutic papilloma virus vaccines
EP4637812A1 (en) 2022-12-19 2025-10-29 GlaxoSmithKline Biologicals S.A. Hepatitis b compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US587673A (en) 1897-08-03 higgins
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JP2682061B2 (ja) 1988-10-07 1997-11-26 藤沢薬品工業株式会社 ペプチドの分子内ジスルフィド結合の形成法
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6245904B1 (en) * 1995-09-14 2001-06-12 The University Of Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific T-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
CA2331846C (en) * 1998-05-13 2010-01-12 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
GB0208817D0 (en) 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
EP1957528B1 (en) * 2005-11-30 2012-11-07 University of Copenhagen A nucleotide vaccine
US20080095798A1 (en) 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
US9085638B2 (en) * 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US8748130B2 (en) * 2008-09-02 2014-06-10 Antigen Express, Inc. Human papillomavirus / Ii-Key hybrids and methods of use

Similar Documents

Publication Publication Date Title
JP2012509071A5 (cg-RX-API-DMAC7.html)
RU2011125306A (ru) Праймирование иммунного ответа
JP6321261B2 (ja) ワクチン組成物及びその使用方法
An et al. Silica nanoparticle as a lymph node targeting platform for vaccine delivery
RU2712743C2 (ru) Вакцина против бешенства
Andrianov et al. Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation
Li et al. Rational design of T-cell-and B-cell-based therapeutic cancer vaccines
CA3036742A1 (en) Modified vsv-g and vaccines thereof
AU2016379413A1 (en) Covalent polymer-antigen conjugated particles
Wang et al. Cell penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination
JP2013532971A5 (cg-RX-API-DMAC7.html)
US20040033585A1 (en) Flexible vaccine assembly and vaccine delivery platform
Bolhassani et al. DNA immunization as an efficient strategy for vaccination
Jiang Cell-penetrating peptide-mediated nanovaccine delivery
WO2022043449A1 (en) Vaccines based on an antigen protein fused to a nanostructuring scaffold
Wang et al. Advances of nanotechnology toward vaccine development against animal infectious diseases
Ito et al. Antigen/adjuvant-displaying enveloped viral replica as a self-adjuvanting anti-breast-cancer vaccine candidate
KR20130044204A (ko) 점막 백신
JP5458286B1 (ja) 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル
JP5901084B2 (ja) ペプチドアジュバント
Bae et al. Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery
Jin et al. Administration of soft matter lipid-DNA nanoparticle as the immunostimulant via multiple routes of injection in vivo
WO2005091753A2 (en) Flexible vaccine assembly and vaccine delivery platform
US20050282263A1 (en) Flexible vaccine assembly and vaccine delivery platform
Bolhassani et al. Non-viral delivery systems in gene therapy and vaccine development